| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary target of MSNBA is GLUT5 (glucose transporter type 5), a fructose-specific transporter. GLUT5 is responsible for the facilitated diffusion of fructose across cell membranes. MSNBA is a specific inhibitor of GLUT5 fructose transport. It competitively inhibits GLUT5 fructose uptake in MCF7 cells with a KI of 3.2 ± 0.4 μM.
|
|---|---|
| ln Vitro |
MSNBA is a specific inhibitor of GLUT5 fructose transport. It competitively inhibits GLUT5 fructose uptake in MCF7 cells with a KI of 3.2 ± 0.4 μM. The compound acts as a probe of the GLUT5 transporter. Its specificity for GLUT5 makes it a valuable tool for studying fructose transport and metabolism.
|
| ln Vivo |
In vivo, MSNBA is used to study fructose transport and metabolism. By specifically inhibiting GLUT5, it can modulate fructose uptake and metabolism in various tissues. Its efficacy would be assessed in animal models of metabolic diseases, with endpoints including fructose metabolism, insulin sensitivity, and metabolic parameters.
|
| Enzyme Assay |
In vitro binding and enzyme activity assays for MSNBA typically involve measuring its ability to inhibit GLUT5-mediated fructose uptake. Fructose uptake assays are performed using MCF7 cells or proteoliposomes containing GLUT5. Cells are incubated with radiolabeled fructose in the presence of increasing concentrations of MSNBA, and the inhibition of fructose uptake is measured. The reported KI is 3.2 ± 0.4 μM.
|
| Cell Assay |
Cellular assays for MSNBA involve treating GLUT5-expressing cells (such as MCF7 cells) with the compound and measuring inhibition of fructose uptake. Readouts include reduction of radiolabeled or fluorescent fructose uptake. The compound's specificity for GLUT5 can be confirmed by testing against other glucose transporters.
|
| Animal Protocol |
In vivo efficacy of MSNBA would be evaluated in animal models of metabolic diseases, such as obesity, diabetes, or fructose-induced metabolic disorders. The compound could be administered orally or via injection. Efficacy endpoints would include fructose metabolism, insulin sensitivity, and metabolic parameters.
|
| ADME/Pharmacokinetics |
MSNBA has a molecular weight of 336.32 and a molecular formula of C14H12N2O6S. It is a specific inhibitor of GLUT5 fructose transport. MSNBA competitively inhibits GLUT5 fructose uptake in MCF7 cells with a KI of 3.2 ± 0.4 μM. The compound acts as a probe of the GLUT5 transporter. It is for research use only and is not intended for human therapeutic use.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for MSNBA in the provided literature. As a research compound, its safety profile would be an important consideration for in vivo applications. Potential toxicities could be related to its effects on fructose metabolism in various tissues. Standard preclinical safety studies would be required to evaluate its safety for potential therapeutic applications. The compound is for research use only and is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
MSNBA is a specific inhibitor of GLUT5 fructose transport. It competitively inhibits GLUT5 fructose uptake in MCF7 cells with a KI of 3.2 ± 0.4 μM. MSNBA has a molecular formula of C14H12N2O6S and a molecular weight of 336.32. It acts as a probe of the GLUT5 transporter. MSNBA is a research tool for studying fructose transport and metabolism.
|
| Molecular Formula |
C14H12N2O6S
|
|---|---|
| Molecular Weight |
336.319882392883
|
| Exact Mass |
336.041
|
| CAS # |
852702-51-3
|
| PubChem CID |
4783927
|
| Appearance |
Brown to dark brown solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
543
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C)(C1C=CC(=C(C=1)[N+](=O)[O-])NC1=CC=C2C(=C1)OCO2)(=O)=O
|
| InChi Key |
FUVYUOPHDIDJOP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12N2O6S/c1-23(19,20)10-3-4-11(12(7-10)16(17)18)15-9-2-5-13-14(6-9)22-8-21-13/h2-7,15H,8H2,1H3
|
| Chemical Name |
N-(4-methylsulfonyl-2-nitrophenyl)-1,3-benzodioxol-5-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (297.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9734 mL | 14.8668 mL | 29.7336 mL | |
| 5 mM | 0.5947 mL | 2.9734 mL | 5.9467 mL | |
| 10 mM | 0.2973 mL | 1.4867 mL | 2.9734 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
